Vascular endothelial growth factor and its inhibitors

Drugs of Today

Volumn 39, Issue SUPPL. C, 2003, Pages 81-93

  Verheul, H M W ^a   Pinedo, H M ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; BEVACIZUMAB; CARBOPLATIN; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; SUNITINIB; THALIDOMIDE; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VATALANIB;

ABDOMINAL PAIN; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTHRITIS; ASTHENIA; ATHEROSCLEROSIS; BLOOD VESSEL PERMEABILITY; BONE MARROW; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL GROWTH; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; DRUG MECHANISM; DRUG MEGADOSE; EDEMA; ENDOTHELIUM CELL; FATIGUE; FECES; FINGER NAIL; HEADACHE; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY CARCINOMA; LETHARGY; NAIL DISEASE; NAUSEA; ORBIT; PROTEIN FUNCTION; SKIN DISEASE; STEM CELL; TUMOR GROWTH; URINE; VERTIGO;

ANGIOGENESIS INHIBITORS; ANIMALS; CLINICAL TRIALS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0345530056     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (79)

1. Neufeld, G., Cohen, T., Gengrinovitch, S., Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999, 13: 9-22.
2. Park, J.E., Chen, H.H., Winer, J., Houck, K.A., Ferrara, N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 1994, 269: 25646-54.
3. Carmeliet, P., Ng, Y.S., Nuyens, D. et al. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat Med 1999, 5: 495-502.
4. Carmeliet, P., Ferreira, V., Breier, G. et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996, 380: 435-9.
5. Drake, C.J., Little, C.D. Exogenous vascular endothelial growth factor induces malformed and hyperfused vessels during embryonic neovascularization. Proc Natl Acad Sci USA 1995, 92: 7657-61.
6. Luttun, A., Tjwa, M., Moons, L. et al. Revascularization of ischemic tissues by PIGF treatment and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt-1 antibody. Nature Med 2002, 8: 831-40.
7. Shalaby, F., Rossant, J., Yamaguchi, T.P. et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995, 376: 62-6.
8. Barleon, B., Siemeister, G., Martiny-Baron, G., Weindel, K., Herzog, C., Marme, D. Vascular endothelial growth factor up-regulates its receptor fms-like tyrosine kinase 1 (FLT-1) and a soluble variant of FLT-1 in human vascular endothelial cells. Cancer Res 1997, 57: 5421-5.
9. Shen, B.Q., Lee, D.Y., Gerber, H.P., Keyt, B.A., Ferrara, N., Zioncheck, T.F. Homologous up-regulation of KDR/Flk-1 receptor expression by vascular endothelial growth factor in vitro. J Biol Chem 1998, 273: 29979-85.
10. Gluzman-Poltorak, Z., Cohen, T., Herzog, Y., Neufeld, G. Neuropilin-2 and neuropilin-1 are receptors for the 165-amino acid form of vascular endothelial growth factor (VEGF) and of placenta growth factor-2, but only neuropilin-2 functions as a receptor for the 145-amino acid form of VEGF. J Biol Chem 2000, 275: 18040-5.
11. Soker, S., Takashima, S., Miao, H.Q., Neufeld, G., Klagsbrun, M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998, 92: 735-45.
12. Brambilla, E., Constantin, B., Drabkin, H., Roche, J. Semaphorin SEMA3F localization in malignant human lung and cell lines: A suggested role in cell adhesion and cell migration. Am J Pathol 2000, 156: 939-50.
13. Senger, D.R., Galli, S.J., Dvorak, A.M., Perruzzi, C.A., Harvey, V.S., Dvorak, H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219: 983-5.
14. Verheul, H.M., Hoekman, K., Jorna, A.S., Smit, E.F., Pinedo, H.M. Targeting vascular endothelial growth factor blockade: Ascites and pleural effusion formation. Oncologist 2000, 5: 45-50.
15. Zebrowski, B.K., Liu, W., Ramirez, K., Akagi, Y., Mills, G.B., Ellis, L.M. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 1999, 6: 373-8.
16. Zebrowski, B.K., Yano, S., Liu, W. et al. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res 1999, 5: 3364-8.
17. Leung, D.W., Cachianes, G., Kuang, W.J., Goeddel, D.V., Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246: 1306-9.
18. Connolly, D.T., Heuvelman, D.M., Nelson, R. et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989, 84: 1470-8.
19. Zucker, S., Mirza, H., Conner, C.E. et al. Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: Conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation. Int J Cancer 1998, 75: 780-6.
20. Pepper, M.S., Ferrara, N., Orci, L., Montesano, R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun 1991, 181: 902-6.
21. Verheul, H.M.W., Jorna, A.S., Hoekman, K. et al. Vascular endothelial growth factor stimulated endothelial cells promote adhesion and activation of platelets. Blood 2000, 96: 4216-21.
22. Alon, T., Hemo I, Peér, J., Stone, Keshet, E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995, 1: 1024-8.
23. Kenyon, B.M., Voest, E.E., Chen, C.C., Flynn, E., Folkman, J., D'Amato, R.J. A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci 1996, 37: 1625-32.
24. Ohm J.E., Carbone D.P. VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res 2001, 23: 263-72.
25. Gerber H.P., Malik, A.K., Solar, G.P. et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002, 417: 954-8.
26. Taichman, N.S., Young, S., Cruchley, A.T., Taylor, P., Paleolog, E. Human neutrophils secrete vascular endothelial growth factor. J Leukoc Biol 1997, 62: 397-400.
27. Verheul, H.M.W., Hoekman, K., Luykxde Bakker, S. et al. Platelet: Transporter of vascular endothelial growth factor. Clin Cancer Res 1997, 3: 2187-90.
28. Richard, D.E., Berra, E., Pouyssegur, J. Angiogenesis: How a tumor adapts to hypoxia. Biochem Biophys Res Commun 1999, 266: 718-22.
29. Toi, M., Hoshina, S., Takayanagi, T., Tominaga, T. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res 1994, 85: 1045-9.
30. Jain, R.K., Schlenger, K., Hockel, M., Yuan, F. Quantitative angiogenesis assays: Progress and problems. Nat Med 1997, 3: 1203-8.
31. Carmeliet, P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000, 6: 389-95.
32. Weltermann, A., Wolzt, M., Petersmann, K. et al. Large amounts of vascular endothelial growth factor at the site of hemostatic plug formation in vivo. Arterioscler Thromb Vasc Biol 1999, 19: 1757-60.
33. Linderholm, B., Tavelin, B., Grankvist, K., Henriksson, R. Does vascular endothelial growth factor (VEGF) predict local relapse and survival in radiotherapy-treated node-negative breast cancer? Br J Cancer 1999, 81: 727-32.
34. Takahashi, Y., Kitadai, Y., Bucana, C.D., Cleary, K.R., Ellis, L.M. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995, 55: 3964-8.
35. Weidner, N., Carroll, P.R., Flax, J., Blumenfeld, W., Folkman, J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993, 143: 401-9.
36. Gasparini, G., Toi, M., Gion, M. et al. Prognostic significance of vascular endothelial growth factor protein in nodenegative breast carcinoma. J Natl Cancer Inst 1997, 89: 139-47.
37. Folkman, J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971, 285: 1182-6.
38. Weidner, N., Folkman, J., Pozza, F., Bevilacqua, P. et al. Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992, 84: 1875-87.
39. Gimbrone, M.A., Jr., Leapman, S.B., Cotran, R.S., Folkman, J. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 1972, 136: 261-76.
40. Kondo, Y., Arii, S., Mori, A., Furutani, M., Chiba, T., Imamura, M. Enhancement of angiogenesis, tumor growth, and metastasis by transfection of vascular endothelial growth factor into LoVo human colon cancer cell line. Clin Cancer Res 2000, 6: 622-30.
41. Kim, K.J., Li, B., Winer, J. et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362: 841-4.
42. Skobe, M., Rockwell, P., Goldstein, N., Vosseler, S., Fusenig, N.E. Halting angiogenesis suppresses carcinoma cell invasion. Nat Med 1997, 3: 1222-7.
43. Li, C.Y., Shan, S., Huang, Q. et al. Initial stages of tumor cell-induced angiogenesis: Evaluation via skin window chambers in rodent models. J Natl Cancer Inst 2000, 92: 143-7.
44. Presta, L.G., Chen, H., O'Connor, S.J. et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997, 57: 4593-9.
45. Lin, P., Sankar, S., Shan, S. et al. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ 1998, 9: 49-58.
46. Saleh, M., Stacker, S.A., Wilks, A.F. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res 1996, 56: 393-401.
47. Siemeister, G., Schirner, M., Reusch, P., Barleon, B., Marme, D., Martiny-Baron, G. An antagonistic vascular endothelial growth factor (VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells. Proc Natl Acad Sci USA 1998, 95: 4625-9.
48. Strawn, L.M., McMahon, G., App, H. et al. Flk-1 as a target for tumor growth inhibition. Cancer Res 1996, 56: 3540-5.
49. Brower, V. Tumor angiogenesis - new drugs on the block. Nat Biotechnol 1999, 17: 963-88.
50. Ferrara, N., Davis-Smyth, T. The biology of vascular endothelial growth factor. Endocr Rev 1997, 18: 4-25.
51. Gordon, M.S., Margolin, K., Talpaz, M. et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001, 19: 843-50.
52. Margolin, K., Gordon, M.S., Holmgren, E. et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer. Pharmacologic and long-term safety data. J Clin Oncol 2001, 19: 851-6.
53. Reese, D., Frohlich, M., Bok, R. et al. A phase II trial of humanized monoclonal anti-vascular endothelial growth factor antibody in hormone refractory prostate cancer. Proc Am Soc Clin Oncol 1999, 18: Abst 1355.
54. Yang, J.C., Haworth, L., Steinberg, S.M., Rosenberg, S.A., Novotny, W. A randomized double-blind placebo-controlled trial of bevacizumab (anti-VEGF antibody) demonstrating a prolongation in time to progression in patients with metastatic renal cancer. Proc Am Soc Clin Oncol 2002, 21: Abst 15.
55. Fong, T.A., Shawver, L.K., Sun, L. et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999, 59: 99-106.
56. Rosen, L., Mulay, M., Mayers, A. et al. Phase 1 dose escalating trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies. Proc Am Soc Clin Oncol 1999, 18: Abst 618.
57. Kuenen, B.C., Rosen, L., Smit, E.F. et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 2002, 20: 1657-67.
58. Gajewski, T.F., Flickinger, S., Heimann, R. et al. Phase II study of the anti-angiogenic FLK-1 tyrosine kinase inhibitor SU5416 in melanoma: Initial results. Proc Am Soc Clin Oncol 2001, 20: Abst 1436.
59. Kindler, H.L., Zvogelzang, N.J., Chien, K. et al. SU5416 in malignant mesothelioma: A University of Chicago Phase II consortium study. Proc Am Soc Clin Oncol 2001, 20: Abst 1359.
60. Laird, A.D., Vajkoczy, P., Shawver, L.K. et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 2000, 60: 4152-60.
61. Rosen, L., Hannah, A., Rosen, P. et al. Phase I dose escalating trial of oral SU006668, a novel multiple receptor tyrosine kinase inhibitor in patients with selected advanced malignancies. Proc Am Soc Clin Oncol 2000, 20: Abst 97.
62. Hurwitz, H.I., Eckhardt, S.G., Holden, S.N. et al. A phase I study of ZD6474, an oral VEGF receptor tyrosine kinase inhibitor, in patients with solid tumors. Suppl Clin Cancer Res 2001, 7: Abst 5.
63. Thomas, A., Morgan, B., Rowark, G. et al. Phase I study of the oral vascular endothelial growth factor (VEGF) receptor inhibitor PTK/ZK222584 on a twice daily schedule in patients with cancer. Suppl Clin Cancer Res 2001, 7: Abst 48.
64. Hanahan, D., Weinberg, R.A. The Hallmarks of cancer. Cell 2000, 100: 57-70.
65. Holmgren, L., O'Reilly, M.S., Folkman, J. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med 1995, 1: 149-53.
66. Folkman, J. Incipient angiogenesis. J Natl Cancer Inst 2000, 92: 94-5.
67. Shi, Q., Le, X., Wang, B. et al. Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells. Oncogene 2001, 20: 3751-6.
68. Shima, D.T., Adamis, A.P., Ferrara, N. et al. Hypoxic induction of endothelial cell growth factors in retinal cells: Identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med 1995, 1: 182-93.
69. Satake, S., Kuzuya, M., Miura, H. et al. Up-regulation of vascular endothelial growth factor in response to glucose deprivation. Biol Cell 1998, 90: 161-8.
70. McDonald, D.M., Foss, A.J. Endothelial cells of tumor vessels: Abnormal but not absent. Cancer Metastasis Rev 2000, 19: 109-20.
71. Kerbel, R.S., Yu, J., Tran, J. et al. Possible mechanisms of acquired resistance to anti-angiogenic drugs: Implications for the use of combination therapy approaches. Cancer Metastasis Rev 2001, 20: 79-86.
72. Hsu, C., Chen, C., Chen, L., Wu, C., Hsieh, F., Cheng, A. Use of thalidomide in the treatment of advanced hepatocellular carcinoma: With emphasis on using power Doppler sonography to evaluate the vascularity of the tumor and its correlation with tumour response. Suppl Clin Cancer Res 2001, 7: Abst 67.
73. Waas, J., Overmoyer, B., Dowlati, A. et al. Circulating cellular adhesion molecules in patients receiving SU5416. Suppl Clin Cancer Res 2001, 7: Abst 56.
74. Dowlati, A., Haaga, J., Remick, S.C. et al. Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation. Clin Cancer Res 2001, 7: 2971-6.
75. Mancuso, P., Burlini, A., Pruneri, G., Goldhirsch, A., Martinelli, G., Bertolini, F. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2001, 97: 3658-61.
76. Marx, G.M., Steer, C.B., Harper, P., Pavlakis, N., Rixe, O., Khayat, D. Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: Time to take stock! J Clin Oncol 2002, 20: 1446-8.
77. Sledge, G., Miller, K., Novotny, W., Gaudreault, J., Ash, M., Cobleigh, M. A phase II trial of single-agent Rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) in patients with relapsed metastatic breast cancer. Proc Am Soc Clin Oncol 2000: Abst 5C.
78. Bergsland, E., Hurwitz, H., Fehrenbacher, L. et al. A randomized phase II trial comparing rhuMab rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial growth factor) plus 5-fluorouracil/leucovorin (FU/LV) to FU/LV alone in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2000: Abst 939.
79. DeVore, R.F., Fehrenbacher, L., Herbst, R.S. et al. A randomized phase II trial comparing recombinant humanized monoclonal antibody to vascular endothelial growth factor plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC. Proc Am Soc Clin Oncol 2000: Abst 1896.